Milestone Pharmaceuticals (Milestone Pharmaceuticals) Enterprise Value : $56.50 Mil (As of May. 24, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Milestone Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Milestone Pharmaceuticals's Enterprise Value is $56.50 Mil. Milestone Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-51.70 Mil. Therefore, Milestone Pharmaceuticals's EV-to-EBIT ratio for today is -1.09.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Milestone Pharmaceuticals's Enterprise Value is $56.50 Mil. Milestone Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-51.60 Mil. Therefore, Milestone Pharmaceuticals's EV-to-EBITDA ratio for today is -1.09.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Milestone Pharmaceuticals's Enterprise Value is $56.50 Mil. Milestone Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Milestone Pharmaceuticals's EV-to-Revenue ratio for today is .

Milestone Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Milestone Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Milestone Pharmaceuticals Enterprise Value Chart

Milestone Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Enterprise Value

Get a 7-Day Free Trial

273.03

58.48

82.39

73.68

41.69

Milestone Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Enterprise Value	Get a 7-Day Free Trial															80.08	57.82	79.08	41.69	58.33

Competitive Comparison of Milestone Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, Milestone Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Milestone Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Milestone Pharmaceuticals's Enterprise Value falls into.

Milestone Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Milestone Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

	Enterprise Value (A: Dec. 2023 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	55.916777	+	0	+	51.229
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	0.546	+	0	-	66.003
=	41.69

Milestone Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

	Enterprise Value (Q: Mar. 2024 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	95.308908	+	0	+	51.95
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	0.555	+	0	-	89.481
=	58.33

Milestone Pharmaceuticals (NAS:MIST) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Milestone Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	56.496	/	-51.699
	=	-1.09

Milestone Pharmaceuticals's current Enterprise Value is $56.50 Mil.
Milestone Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.70 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Milestone Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA(TTM)
	=	56.496	/	-51.597
	=	-1.09

Milestone Pharmaceuticals's current Enterprise Value is $56.50 Mil.
Milestone Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.60 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Milestone Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	56.496	/	0
	=

Milestone Pharmaceuticals's current Enterprise Value is $56.50 Mil.
Milestone Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Milestone Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Milestone Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Milestone Pharmaceuticals (Milestone Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Milestone Pharmaceuticals Inc (NAS:MIST) » Definitions » Enterprise Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, QC, CAN, H4M 2X6

Website

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT.

Executives

Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
David Bharucha	officer: Chief Medical Officer	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Debra K. Liebert	director	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6
Richard C Pasternak	director	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M2X6
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Robert James Wills	director	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jeffrey Edward Nelson	officer: Chief Operating Officer	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Paul F Truex	director	PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Fonds De Solidarite Des Travailleurs Du Quebec	10 percent owner	545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Amit Hasija	officer: CFO & EVP of Corp. Development	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M 2X6
Lorenz Muller	officer: Chief Commercial Officer	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6